Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada

Cephalalgia

Volumn 26, Issue 5, 2006, Pages 578-588

  Jelinski, S E ^a   Becker, W J ^a,g   Christie, S N ^b   Giammarco, R ^c   Mackie, G F ^d   Gawel, M J ^e   Eloff, A G ^a   Magnusson, J E ^f  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Richmond Hospital   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g FOOTHILLS HOSPITAL   (Canada)

Author keywords

Medication overuse; Migraine; Pharmacotherapy; Prophylactic treatment; Symptomatic treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ATENOLOL; BARBITURIC ACID DERIVATIVE; BOTULINUM TOXIN A; CHLORPROMAZINE; CODEINE; DIMENHYDRINATE; ERGOTAMINE DERIVATIVE; FLUNARIZINE; GABAPENTIN; GASTROINTESTINAL AGENT; METOCLOPRAMIDE; NADOLOL; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; PARACETAMOL; PIZOTIFEN; PROCHLORPERAZINE; PROPRANOLOL; ROFECOXIB; STEROID; TOPIRAMATE; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CHILD; CLINICAL FEATURE; CONSULTATION; DISEASE SEVERITY; DRUG ABUSE; DRUG UTILIZATION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MIGRAINE; PATIENT REFERRAL; TREATMENT DURATION; TREATMENT INDICATION;

ADOLESCENT; ADULT; ANALGESICS; CANADA; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROLOGY; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; REFERRAL AND CONSULTATION;

EID: 33645971629     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2005.01077.x     Document Type: Article

References (47)

1. Hopkins A Menken M DeFriese G A record of patient encounters in neurological practice in the United Kingdom J Neurol Neurosurg Psychiatry 1989 52 436 8
2. Cockerell OC Goodridge DM Brodie D Sander JW Shorvon SD Neurological disease in a defined population: the results of a pilot study in two general practices Neuroepidemiology 1996 15 73 82
3. Wiles CM Lindsay M General practice referrals to a department of neurology J R Coll Physicians Lond 1996 30 426 31
4. Bekkelund SI Albretsen C Evaluation of referrals from general practice to a neurological department Fam Pract 2002 19 297 9
5. Stewart WF Celentano DD Linet MS Disability, physician consultation, and use of prescription medications in a population-based study of headache Biomed Pharmacother 1989 43 711 8
6. Lavados PM Tenhamm E Consulting behaviour in migraine and tension-type headache sufferers: a population survey in Santiago, Chile Cephalalgia 2001 21 733 7
7. Wang SJ Fuh JL Young YH Lu SR Shia BC Frequency and predictors of physician consultations for headache Cephalalgia 2001 21 25 30
8. Gesztelyi G Bereczki D Primary headaches in an outpatient neurology headache clinic in East Hungary Eur J Neurol 2004 11 389 95
9. O'Brien B Goeree R Streiner D Prevalence of migraine headache in Canada: a population-based survey Int J Epidemiol 1994 23 1020 6
10. Von Korff M Stewart WF Simon DJ Lipton RB Migraine and reduced work performance: a population-based diary study Neurology 1998 50 1741 5
11. Gerth WC Carides GW Dasbach EJ Visser WH Santanello NC The multinational impact of migraine symptoms on healthcare utilisation and work loss Pharmacoeconomics 2001 19 197 206
12. Lipton RB Bigal ME Kolodner K Stewart WF Liberman JN Steiner TJ The family impact of migraine. population-based studies in the USA and UK Cephalalgia 2003 23 429 40
13. Terwindt GM Ferrari MD Tijhuis M Groenen SM Picavet HS Launer LJ The impact of migraine on quality of life in the general population: the GEM study Neurology 2000 55 624 9
14. Edmeads J Findlay H Tugwell P Pryse-Phillips W Nelson RF Murray TJ Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey Can J Neurol Sci 1993 20 131 7
15. Lipton RB Scher AI Kolodner K Liberman J Steiner TJ Stewart WF Migraine in the United States: epidemiology and patterns of health care use Neurology 2002 58 885 94
16. Riess CM Becker WJ Robertson M Episodic cluster headache in a community: clinical features and treatment Can J Neurol Sci 1998 25 141 5
17. Pryse-Phillips WE Dodick DW Edmeads JG Gawel MJ Nelson RF Purdy RA et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society CMAJ 1997 156 1273 87
18. Silberstein SD Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 2000 55 754 62
19. Snow V Weiss K Wall EM Mottur-Pilson C Pharmacologic management of acute attacks of migraine and prevention of migraine headache Ann Intern Med 2002 137 840 9
20. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders cranial neuralgias and facial pain Cephalalgia 1988 8 Suppl. 7 1 96
21. Silberstein SD Lipton RB Sliwinski M Classification of daily and near-daily headaches: field trial of revised IHS criteria Neurology 1996 47 871 5
22. Siberstein SD Lipton RB Solomon S Mathew NT Classification of daily and near-daily headaches: proposed revisions to the IHS criteria Headache 1994 34 1 7
23. Kosinski M Bayliss MS Bjorner JB Ware JE Jr. Garber WH Batenhorst A et al. A six-item short-form survey for measuring headache impact: the HIT-6 Qual Life Res 2003 12 963 74
24. Nachit-Ouinekh F Dartigues JF Henry P Becg JP Chastan G Lemaire N El Hasnaoui A Use of the headache impact test (HIT-6) in general practice: relationship with quality of life and severity Eur J Neurol 2005 12 189 93
25. Stewart WF Lipton RB Whyte J Dowson A Kolodner K Liberman JN Sawyer J An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score Neurology 1999 53 988 94
26. Stewart WF Lipton RB Kolodner K Liberman J Sawyer J Reliability of the migraine disability assessment score in a population-based sample of headache sufferers Cephalalgia 1999 19 107 14 ; discussion 74
27. Stewart WF Lipton RB Kolodner KB Sawyer J Lee C Liberman JN Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers Pain 2000 88 41 52
28. Dowson AJ Lipscombe S Sender J Rees T Watson D New guidelines for the management of migraine in primary care Curr Med Res Opin 2002 18 414 39
29. Von Korff M Black LK Saunders K Galer BS Headache medication-use among primary care headache patients in a health maintenance organization Cephalalgia 1999 19 575 80 ; discussion 41 2
30. Rahimtoola H Buurma H Tijssen CC Leufkens HG Egberts AC Incidence and determinants of migraine prophylactic medication in the Netherlands Eur J Clin Pharmacol 2002 58 149 55
31. Ferrari A Pasciullo G Savino G Cicero AF Ottani A Bertolini A Sternieri E Headache treatment before and after the consultation of a specialized centre: a pharmacoepidemiology study Cephalalgia 2004 24 356 62
32. Lipton RB Stewart WF Celentano DD Reed ML Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis Arch Intern Med 1992 152 1273 8
33. Von Korff M Galer BS Stang P Chronic use of symptomatic headache medications Pain 1995 62 179 86
34. Bigal ME Rapoport AM Sheftell FD Tepper SJ Lipton RB Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes Cephalalgia 2004 24 483 90
35. Katsarava Z Muessig M Dzagnidze A Fritsche G Diener HC Limmroth V Medication overuse headache: rates and predictors for relapse in a 4-year prospective study Cephalalgia 2005 25 12 5
36. Cortelli P Dahlof C Bouchard J Heywood J Jansen JP Pham S et al. A multinational investigation of the impact of subcutaneous sumatriptan. III. Workplace productivity and non-workplace activity Pharmacoeconomics 1997 11 Suppl. 1 35 42
37. Dahlof C Bouchard J Cortelli P Heywood J Jansen JP Pham S et al. A multinational investigation of the impact of subcutaneous sumatriptan. II. Health-related quality of life Pharmacoeconomics 1997 11 Suppl. 1 24 34
38. Mathew NT Reuveni U Perez F Transformed or evolutive migraine Headache 1987 27 102 6
39. Mathew NT Drug-induced headache Neurol Clin 1990 8 903 12
40. Mathew NT Transformed migraine Cephalalgia 1993 13 Suppl. 12 78 83
41. Katsarava Z Fritsche G Muessig M Diener HC Limmroth V Clinical features of withdrawal headache following overuse of triptans and other headache drugs Neurology 2001 57 1694 8
42. Dodick DW Debate: analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is not a cause of chronic daily headache Headache 2002 42 547 54
43. Hamalainen ML Hoppu K Valkeila E Santavuori P Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study Neurology 1997 48 103 7
44. Brandes JL Saper JR Diamond M Couch JR Lewis DW Schmitt J et al. Topiramate for migraine prevention: a randomized controlled trial Jama 2004 291 965 73
45. Diener HC Tfelt-Hansen P Dahlof C Lainez MJ Sandrini G Wang SJ et al. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control J Neurol 2004 251 943 50
46. Silberstein SD Neto W Schmitt J Jacobs D Topiramate in migraine prevention: results of a large controlled trial Arch Neurol 2004 61 490 5
47. Mei D Capuano A Vollono C Evangelista M Ferraro D Tonali P Di Trapani G Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study Neurol Sci 2004 25 245 50